vs
CorMedix Inc.（CRMD）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $128.6M、CorMedix Inc.の約1.5倍）
CorMedix Inc.は商業段階のバイオ医薬品企業であり、感染症、炎症性疾患、心腎疾患の予防・治療に用いる新規治療薬の開発・事業化に注力しています。主力候補はカテーテル関連血流感染症を対象とし、主に北米・欧州の集中治療患者や長期透析患者層にサービスを提供しています。
CRMD vs RILY — 直接比較
売上が大きい
RILY
1.5倍大きい
$128.6M
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $128.6M | $188.3M |
| 純利益 | — | $90.3M |
| 粗利率 | 83.4% | 79.5% |
| 営業利益率 | 46.0% | 32.3% |
| 純利益率 | — | 47.9% |
| 売上前年比 | — | -21.9% |
| 純利益前年比 | — | 1710.8% |
| EPS（希薄化後） | $0.20 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上CRMDRILY
| Q4 25 | $128.6M | $188.3M | ||
| Q3 25 | $104.3M | $215.3M | ||
| Q2 25 | $39.7M | $188.2M | ||
| Q1 25 | $39.1M | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | — | $263.4M |
純利益CRMDRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $108.6M | $91.1M | ||
| Q2 25 | $19.8M | $139.5M | ||
| Q1 25 | $20.6M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | — | $-49.2M |
粗利率CRMDRILY
| Q4 25 | 83.4% | 79.5% | ||
| Q3 25 | 89.3% | 83.7% | ||
| Q2 25 | 95.3% | 81.3% | ||
| Q1 25 | 95.9% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
営業利益率CRMDRILY
| Q4 25 | 46.0% | 32.3% | ||
| Q3 25 | 49.2% | 30.4% | ||
| Q2 25 | 49.2% | 5.7% | ||
| Q1 25 | 51.5% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | — | -6.1% |
純利益率CRMDRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | 104.1% | 42.3% | ||
| Q2 25 | 49.9% | 74.1% | ||
| Q1 25 | 52.8% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | — | -18.7% |
EPS（希薄化後）CRMDRILY
| Q4 25 | $0.20 | $2.78 | ||
| Q3 25 | $1.26 | $2.91 | ||
| Q2 25 | $0.28 | $4.50 | ||
| Q1 25 | $0.30 | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | — | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $148.5M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $405.3M | $-171.5M |
| 総資産 | $826.1M | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資CRMDRILY
| Q4 25 | $148.5M | $226.6M | ||
| Q3 25 | $55.7M | $184.2M | ||
| Q2 25 | $190.7M | $267.4M | ||
| Q1 25 | $77.5M | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | — | $190.7M |
総負債CRMDRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本CRMDRILY
| Q4 25 | $405.3M | $-171.5M | ||
| Q3 25 | $374.1M | $-260.5M | ||
| Q2 25 | $220.6M | $-351.7M | ||
| Q1 25 | $114.9M | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | — | $228.4M |
総資産CRMDRILY
| Q4 25 | $826.1M | $1.7B | ||
| Q3 25 | $750.9M | $1.7B | ||
| Q2 25 | $252.6M | $1.5B | ||
| Q1 25 | $149.6M | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $5.0B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $94.5M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $92.7M | — |
| FCFマージンFCF / 売上 | 72.1% | — |
| 設備投資強度設備投資 / 売上 | 1.3% | — |
| キャッシュ転換率営業CF / 純利益 | — | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $172.8M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローCRMDRILY
| Q4 25 | $94.5M | $26.2M | ||
| Q3 25 | $30.9M | $-60.6M | ||
| Q2 25 | $30.0M | $-25.6M | ||
| Q1 25 | $19.7M | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | — | $135.4M |
フリーキャッシュフローCRMDRILY
| Q4 25 | $92.7M | — | ||
| Q3 25 | $30.4M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
FCFマージンCRMDRILY
| Q4 25 | 72.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 75.4% | — | ||
| Q1 25 | 50.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
設備投資強度CRMDRILY
| Q4 25 | 1.3% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュ転換率CRMDRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | 0.28× | -0.66× | ||
| Q2 25 | 1.51× | -0.18× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
